We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+20.44%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$476M
AUM Growth
-$38.3M
(-7.4%)
Cap. Flow
-$67.9M
Cap. Flow
% of AUM
-14.26%
Top 10 Holdings %
Top 10 Hldgs %
34.45%
Holding
94
New
29
Increased
20
Reduced
12
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$16.4M |
| 2 |
Quest Diagnostics
DGX
|
+$14.4M |
| 3 |
Cigna
CI
|
+$14.2M |
| 4 |
Universal Health Services
UHS
|
+$11.8M |
| 5 |
Intuitive Surgical
ISRG
|
+$10.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$16.2M |
| 2 |
CRISPR Therapeutics
CRSP
|
+$14.4M |
| 3 |
Boston Scientific
BSX
|
+$13.6M |
| 4 |
Biogen
BIIB
|
+$13.3M |
| 5 |
CVS Health
CVS
|
+$12.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Keros Therapeutics
KROS
$211M
| $2.88M | 0.6% |
+60,000
| New | +$2.8M |
|
|
KYNB
52
Kyntra Bio
KYNB
$28.6M
| $2.8M | 0.59% |
+7,000
| New | +$2.68M |
|
53
Kymera Therapeutics
KYMR
$9.11B
| $2.5M | 0.52% |
+100,000
| New | +$2.67M |
|
54
DaVita
DVA
$11.4B
| $2.46M | 0.52% |
33,000
-42,000
| -56% | -$3.26M |
|
|
RXDX
55
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $2.2M | 0.46% |
+20,000
| New | +$1.3M |
|
|
RAPT
56
DELISTED
RAPT Therapeutics
RAPT
| $2.16M | 0.45% |
+13,625
| New | +$2.18M |
|
57
iRhythm Holdings
IRTC
$4.02B
| $1.87M | 0.39% |
20,000
-30,000
| -60% | -$3.27M |
|
58
TG Therapeutics
TGTX
$7.64B
| $1.77M | 0.37% |
+150,000
| New | +$1.09M |
|
59
Supernus Pharmaceuticals
SUPN
$2.73B
| $1.43M | 0.3% |
+40,000
| New | +$1.39M |
|
|
LBPH
60
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $792K | 0.17% |
243,000
+133,000
| +121% | +$534K |
|
61
Dianthus Therapeutics
DNTH
$6.07B
| $164K | 0.03% |
26,000
+2,437
| +10% | +$43.1K |
|
62
Agios Pharmaceuticals
AGIO
$1.95B
| – | – |
-100,000
| Closed | -$2.83M |
|
63
Alkermes
ALKS
$8.26B
| – | – |
-200,000
| Closed | -$4.47M |
|
|
AMED
64
DELISTED
Amedisys
AMED
| – | – |
-33,000
| Closed | -$3.19M |
|
|
APLS
65
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-70,000
| Closed | -$4.78M |
|
66
Arcturus Therapeutics
ARCT
$214M
| – | – |
-130,000
| Closed | -$1.93M |
|
|
67
Baxter International
BAX
$14.3B
| – | – |
-300,000
| Closed | -$16.2M |
|
|
68
Biogen
BIIB
$30.1B
| – | – |
-50,000
| Closed | -$13.3M |
|
|
BPMC
69
DELISTED
Blueprint Medicines
BPMC
| – | – |
-93,000
| Closed | -$6.13M |
|
|
70
Boston Scientific
BSX
$74.2B
| – | – |
-350,000
| Closed | -$13.6M |
|
|
71
CRISPR Therapeutics
CRSP
$5.23B
| – | – |
-220,000
| Closed | -$14.4M |
|
|
72
CVS Health
CVS
$120B
| – | – |
-130,000
| Closed | -$12.4M |
|
73
Danaher
DHR
$146B
| – | – |
-33,840
| Closed | -$7.75M |
|
74
Denali Therapeutics
DNLI
$3.95B
| – | – |
-115,000
| Closed | -$3.53M |
|
75
Design Therapeutics
DSGN
$915M
| – | – |
-125,000
| Closed | -$2.09M |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q4 2022 Portfolio in Review
As of Q4 2022, Integral Health Asset Management held 94 positions worth $476M, down 7.4% from $515M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Integral Health Asset Management withdrew a net $67.9M in Q4 2022, closing 33 positions and reducing 12 holdings. Its most notable exit was Baxter International, an estimated $16.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 96% a quarter earlier.
Against the trend, Integral Health Asset Management opened a new position in Moderna worth $18M.
- Integral Health Asset Management's largest Q4 2022 buy was Moderna: 100,000 shares worth $18M.
- Integral Health Asset Management added most to BioMarin Pharmaceuticals in Q4 2022, an estimated $5.91M increase.
- Integral Health Asset Management's biggest Q4 2022 reduction was Envista, cutting an estimated $11.6M.
- Integral Health Asset Management fully exited Baxter International in Q4 2022, selling an estimated $16.2M.
- Integral Health Asset Management's ten largest holdings make up 34% of its $476M portfolio in Q4 2022.
- Integral Health Asset Management opened 29 new positions and closed 33 in Q4 2022.
- Integral Health Asset Management's portfolio value fell 7.4% quarter-over-quarter to $476M.
Based on Integral Health Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.